<DOC>
	<DOCNO>NCT02001987</DOCNO>
	<brief_summary>This two part , multi-center , open-label , single-arm study evaluate efficacy safety RoActemra/Actemra monotherapy combination non-biologic disease modify antirheumatic drug ( DMARDs ) patient moderate severe rheumatoid arthritis inadequate response intolerant non-biologic DMARDs biologic therapy . 162 mg RoActemra/Actemra administer week subcutaneous injection 76 week .</brief_summary>
	<brief_title>A Study Of RoActemra/Actemra ( Tocilizumab ) Tocilizumab-Naive Patients With Rheumatoid Arthritis With Inadequate Response Non-Biologic Disease-Modifying Antirheumatic Drugs ( DMARDs ) Biologic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Patients &gt; / = 18 year age Patients diagnosis active RA accord revise ACR criterion EULAR/ACR criterion receive outpatient treatment Oral corticosteroid ( &lt; / = 10 mg/day prednisone equivalent ) nonsteroidal antiinflammatory drug ( NSAIDs ) , permit nonbiologic DMARDs allow stable dose regimen &gt; / = 20 mm/h swell joint count ( SJC ) &gt; / = 3 ( base 44 joint ) Inadequate response ( IR ) tumor necrosis factor , Abatacept and/or nonbiological diseasemodifying antirheumatic drug ( DMARDs ) Major surgery ( include joint surgery ) within 8 week prior Screening plan major surgery within 6 month follow Baseline Rheumatic autoimmune disease RA ; Secondary Sj√∂gren 's syndrome RA permit . Functional Class IV define ACR Classification Functional Status Rheumatoid Arthritis Diagnosis juvenile idiopathic arthritis juvenile RA and/or RA age 16 Prior history current inflammatory joint disease RA Exposure RoActemra/Actemra time prior Baseline Treatment investigational agent within 4 week Screening Previous treatment celldepleting therapy , include investigational agent approve therapy alkylating agent chlorambucil , total lymphoid irradiation Treatment IV gamma globulin , plasmapheresis within 6 month Baseline Intraarticular parenteral corticosteroid within 4 week prior Baseline Immunization live/attenuated vaccine within 4 week prior Baseline History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody Serious uncontrolled concomitant disease significant condition History diverticulitis , diverticulosis require antibiotic treatment , chronic ulcerative low GI disease Current history recurrent bacterial , viral , fungal , mycobacterial , infection Any infection require hospitalization treatment IV antibiotic within 4 week Screening oral antibiotic within 2 week Screening Active TB require treatment within previous 3 year Positive hepatitis B C Primary secondary immunodeficiency disorder Active cancer , cancer diagnose within previous 10 year ( except nonmelanoma skin cancer carcinoma situ cervix treat excise consider resolve ) , breast cancer diagnose within previous 20 year History alcohol , drug , chemical abuse within 1 year prior Screening Neuropathies condition might interfere pain evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>